Obagi C RX Clarifying Serum Normal to Oily
Hyperpigmentation, sun damage, and age spots
Uneven skin tone
The appearance fine lines and wrinkles
Dry, normal, or oily skin
Improves hyperpigmentation (brown spots)
Provides a lighter, more even-toned complexion
An exfoliator helps support skin turnover through gentle exfoliation
10% L-ascorbic acid (Vitamin C) helps defend against free radicals
A broad spectrum sunscreen helps protect against harmful UVA and UVB rays
Contains 4% hydroquinone to reduce hyperpigmentation, such as dark spots and melasma, for a lighter, more even skin tone. Also contains 10% L-ascorbic acid (Vitamin C) to help defend against free radicals and address the appearance of aging skin.
Effective prescription 4% hydroquinone that helps correct hyperpigmentation, such as dark spots, sun spots, age spots, melasma, and other types of discoloration, for a healthier-looking, more even skin tone.*
This product requires a prescription which we offer for free through our telemedicine partner My Doctror's Live. After you complete your purchase, we will reach out to you about scheduling a quick 5 minute telemedicine appointment. To learn more about My Doctor's Live, please visit My Doctor's Live | Totality Skincare (totality-skincare.com)
10% L-ascorbic Acid
Early Intervention for Signs of Skin Damage
With Obagi-C Rx, you’re on your way to softer, smoother, radiant, and more even-looking skin. The Obagi-C Rx System offers 4% hydroquinone to reduce hyperpigmentation, and other key ingredients that help address the signs of skin aging to maintain younger-looking skin.
Obagi-C Rx System products are ideal if you have:
Clinically Supported Ingredients
Prescription 4% hydroquinone
Other key ingredients that address the signs of skin aging
Deep Skin Absorption
When the Obagi-C Rx C-Clarifying Serum with C-Balancing Toner were compared to SkinCeuticals Phloretin CF®, another leading Vitamin C product, more Vitamin C remained in the skin at 24 hours.1,*
*Based on in vitro studies. Clinical significance has not been established.
Reference: 1. Lehman PA, Investigator, Cetero Research. Evaluation of the percutaneous absorption of 14C-ascorbic acid, in vitro, using the Franz human skin finite dose model (protocol R09-0715). Data on file.
- Product Details